Kineret® - Reimbursement

Reimbursement


	The Kineret Reimbursement Hotline Phone: 866.547.0644 Fax: 866.549.7219 Reimbursement Form Insurance Verification Request Form Patient Assistance Form PAP Application Form

	ABOUT KINERET^® ABOUT IL-1 PROFESSIONAL RESOURCES REIMBURSEMENT IMPORTANT PRODUCT SAFETY INFORMATION GLOSSARY

Kineret^® (anakinra) is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs). Kineret^® can be used alone or in combination with DMARDs other than tumor necrosis factor (TNF) blocking agents. In clinical trials, there was a risk of serious infections (2% in Kineret^® patients vs. less than 1% in placebo patients). Kineret^® should be discontinued if a patient develops an infection, however most patients can continue taking Kineret^® after their infection resolves. Kineret^® should not be used with TNF-blocking agents such as etanercept, adalimumab, and infliximab. A 7% rate of serious infections was observed in a 24-week study of concurrent administration of Kineret^® and etanercept. Kineret^® is contraindicated in patients with known hypersensitivity to E coli-derived proteins, Kineret^®, or any components of the product. The most common side effect in clinical trials was injection site reaction, which was usually mild and characterized by redness, swelling, and pain.
Biovitrum.com \| Site Map © 2008 Biovitrum Ab (publ). All rights reserved. This site is intended for U.S. audiences only.